The agenda for the 18 March Transparency Commission meeting is now available.  The Commission will consider the following technologies:

• Idursulfase (Elaprase) - review of SMR & ASMR
• Apixaban (Eliquis) - new indication
• Everolimus (Afinitor) - review of SMR & ASMR
• Adalimumab (Humira) - new indication
• Bevacizumab (Avastin) - new indication
• Albumin (human) (Rotop-NanoHSA) - new formulation
• Ulipristal acetate (Esmya) - new formulation

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-03/odj_ct_18032015_internet.pdf [French]